Last reviewed · How we verify
NCT03324542: OIVAEGFFAMDIT
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
trial testing Aflibercept [Eylea] in AMD in 63 participants. Completed in 15 October 2017.
13 October 2017
Quick facts
| Lead sponsor | Changhua Christian Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 63 |
| Start date | 3 April 2017 |
| Primary completion | 13 October 2017 |
| Estimated completion | 15 October 2017 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Aflibercept [Eylea]
Conditions studied
- AMD — all drugs for AMD →
Sponsor
Changhua Christian Hospital
Who can join
Eligibility, any sex, with AMD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Purpose To report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan. Method Retrospective case series of patients with nAMD that were treated with intravitreal injection of anti-VEGF and had a minimum follow up of 48 months. Every patient was initially treated with 3 loading doses of either bevacizumab or ranibizumab, followed by a loose treat and extend regimen. Eyes were divided into 2 groups according to whether aflibercept was later used as a rescue therapy (group 2) or not (group 1). Patients underwent best-corrected visual acuity (BCVA) testing, optical coherence tomography, and ophthalmic examination at baseline and all the scheduled follow-up visits.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Real-world outcomes of intravitreal antivascular endothelial growth factors for neovascular age-related macular degeneration in Taiwan: A 4-year longitudinal study.
Yang BC, Chou TY, Chen SN. · · 2019 · cited 5× · PMID 31942430 · DOI 10.4103/tjo.tjo_34_19
Verify or expand the search:
- PubMed search for NCT03324542
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for AMD
Currently open trials in the same condition.
- NCT07216677 — A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseas · active not recruiting
- NCT01432847 — Cell Collection to Study Eye Diseases · recruiting
Other Changhua Christian Hospital trials
Trials by the same sponsor.
- NCT07040215 — Effects on Subacute Stroke With Robotic Assistive Gait Training · NA · recruiting
- NCT06970834 — Explore the Effect of Bitter Melon Peptides on Glycemic Control and Metabolic Indicators in Diabetic Patients · NA · not yet recruiting
- NCT06432153 — Tampa Scale of Kinesiophobia for Heart Taiwan Version Validation · not yet recruiting
- NCT06334237 — Psychosomatic Factors Influencing the Efficacy of Holistic Care for Migraine · recruiting
- NCT06118294 — Efficacy of Probiotics for Parkinson Disease (PD) · NA · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03324542 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhua Christian Hospital
- Last refreshed: 20 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03324542.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing